Results for
"[search-keyword]"
Sponsor content
179 result(s) found, displaying 21 to 30
-
Prescription medicine registrationActive ingredients: vedolizumab.
-
Australian Public Assessment Report (AusPAR)AusPAR for Exkivity (Mobocertinib) for treatment of patients with locally advanced or metastatic non-small lung cancer.
-
Designation or determinationOrphan drug
-
Prescription medicine decision summaryLivtencity (maribavir) is approved to treat cytomegalovirus (CMV).
-
Prescription medicine registrationActive ingredients: maribavir.
-
Designation or determinationOrphan drug
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Prescription medicine decision summaryTGA decision: Exkivity (mobocertinib) is approved to treat lung cancer
-
Prescription medicine registrationActive ingredients: mobocertinib succinate.